Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study.

MLA

Al-Mistarehi, Abdel-Hameed W., et al. “Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study.” Cureus, vol. 16, no. 8, Aug. 2024, p. e67467. EBSCOhost, https://doi.org/10.7759/cureus.67467.

APA

Al-Mistarehi, A.-H. W., El-Akawi, S., Kheirallah, K. A., Bani Ata, E. M., Zaitoun, K. J., Khassawneh, A. B., Jarrah, A., Alzoubi, H. M., Al-Azzam, S., Karasneh, R. A., Altawalbeh, R. B., & Khassawneh, B. (2024). Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study. Cureus, 16(8), e67467. https://doi.org/10.7759/cureus.67467

Chicago

Al-Mistarehi, Abdel-Hameed W, Shadi El-Akawi, Khalid A Kheirallah, Ehab M Bani Ata, Khaled J Zaitoun, Ahmad B Khassawneh, Abdullah Jarrah, et al. 2024. “Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study.” Cureus 16 (8): e67467. doi:10.7759/cureus.67467.